

California State University, Monterey Bay

Digital Commons @ CSUMB

Mathematics and Statistics Faculty
Publications and Presentations

Mathematics and Statistics

2017

Model Averaging with AIC Weights for Hypothesis Testing of Hormesis at Low Doses

Steven B. Kim

California State University, Monterey Bay, stkim@csumb.edu

Nathan Sanders

Follow this and additional works at: https://digitalcommons.csumb.edu/math_fac

Recommended Citation

Kim, Steven B. and Sanders, Nathan, "Model Averaging with AIC Weights for Hypothesis Testing of Hormesis at Low Doses" (2017). *Mathematics and Statistics Faculty Publications and Presentations*. 2. https://digitalcommons.csumb.edu/math_fac/2

This Article is brought to you for free and open access by the Mathematics and Statistics at Digital Commons @ CSUMB. It has been accepted for inclusion in Mathematics and Statistics Faculty Publications and Presentations by an authorized administrator of Digital Commons @ CSUMB. For more information, please contact digitalcommons@csumb.edu.

Model Averaging with AIC Weights for Hypothesis Testing of Hormesis at Low Doses

Steven B. Kim¹ and Nathan Sanders¹

Abstract

For many dose–response studies, large samples are not available. Particularly, when the outcome of interest is binary rather than continuous, a large sample size is required to provide evidence for hormesis at low doses. In a small or moderate sample, we can gain statistical power by the use of a parametric model. It is an efficient approach when it is correctly specified, but it can be misleading otherwise. This research is motivated by the fact that data points at high experimental doses have too much contribution in the hypothesis testing when a parametric model is misspecified. In dose–response analyses, to account for model uncertainty and to reduce the impact of model misspecification, averaging multiple models have been widely discussed in the literature. In this article, we propose to average semiparametric models when we test for hormesis at low doses. We show the different characteristics of averaging parametric models and averaging semiparametric models by simulation. We apply the proposed method to real data, and we show that P values from averaged semiparametric models are more credible than P values from averaged parametric methods. When the true dose–response relationship does not follow a parametric assumption, the proposed method can be an alternative robust approach.

Keywords

hypothesis testing, hormesis, model misspecification, model averaging, Akaike information criterion

Introduction

In toxicology, hormesis is known to be a biphasic dose–response relationship with a stimulatory response at low doses and an inhibitory response at high doses.^{1,2} In this article, we focus on statistical hypothesis testing for hormesis when the outcome of interest is binary. The null hypothesis is the absence of hormesis denoted by H_0 , and the alternative hypothesis is the presence of hormesis denoted by H_1 . For illustration, 2 models for H_0 and 2 models for H_1 are shown in Figure 1.

Mathematically speaking, we do not have a sign change in the slope of a dose–response curve at low doses when H_0 is true. The slope is entirely positive at low doses (top left in the figure), or the zero slope (ie, flat line) becomes a positive slope after passing some threshold dose point (top right in the figure). On the other hand, we have 1 sign change in the slope at low doses when H_1 is true. The starting slope is negative, and the slope becomes positive at some dose point (bottom left and bottom right in the figure). When H_0 is true, for a given significance level α , we want the probability of rejecting H_0 to be at α or below. When H_1 is true, we want the statistical power as high as possible.

We can increase the statistical power by increasing the number of experimental doses and/or the sample size inside the hormetic range. In such a case, various statistical methods are available including polynomial, fractional polynomial modeling, splines, and nonparametric smoothing techniques.³ However, having such an ideal experimental design is not always possible in practice. Although we prefer statistical methods that require weak assumptions, we need to borrow a parametric assumption to gain statistical power in small-sample studies. Several useful parametric models used in dose–response assessments are equipped in Benchmark Dose Model software.⁴ These models can be modified to quadratic or other alternative forms in order to model a nonmonotonic

¹ Department of Mathematics and Statistics, California State University, Monterey Bay, Seaside, CA, USA

Corresponding Author:

Steven B. Kim, Department of Mathematics and Statistics, California State University, Monterey Bay, 100 Campus Center, Seaside, CA 93955, USA.
Email: stkim@csumb.edu






Figure 1. Dose–response relationships. The top figures show 2 hypothetical monotonic dose–response relationships (null hypothesis, denoted by H_0), and the bottom figures show 2 hypothetical hormetic dose–response relationships (alternative hypothesis, denoted by H_1).

dose–response relationship.^{5–7} A parametric model yields a high statistical power when it is correctly specified, but it can lead to a very low statistical power when it is misspecified. The loss of statistical power due to model misspecification will be shown in this study. There are 2 main reasons. First, the observed data points cannot be adequately modeled by the parametric structure.³ Second, in the case of model misspecification, data points at high doses make situations even worse because they have too much contribution in the parameter estimation. Such data points are called high-leverage points.⁸

We have 2 aims in this article. First, we explicitly address the impact of model misspecification and high-leverage points in parametric modeling when we perform hypothesis testing for hormesis at significance level α . Second, we propose averaging multiple semiparametric models using the weights calculated by Akaike information criterion (AIC).⁹ In both frequentist and Bayesian frameworks, model averaging methods have been widely discussed in cancer risk assessments, particularly for the estimation of benchmark dose. Model averaging allows us to reduce the impact of model misspecification and to account for model uncertainty.^{7,10–13} In this article, we present the simulation study to compare parametric methods and the proposed semiparametric method. For illustration, we apply the methods to some data discussed in Calabrese and Baldwin¹⁴ which seem to show evidence for hormesis at various degrees. In the application, we show that P values calculated from parametric models can be misleading, and P values calculated from the

semiparametric method better match with observed dose–response trend.

Statistical Methods

In this section, we review a logistic regression model in “Logistic Regression Model” subsection. We base our discussion on the logistic model among many parametric models because of its popularity, and the same discussion can be carried out for another form of parameterization. We briefly review the model averaging method based on the AIC in “Model Averaging in Parametric Models (L3 and L4)” subsection. We then discuss the application of model averaging to semiparametric models in “Application of Model Averaging to Semiparametric Models” subsection. More mathematical detail is included in the Appendix.

The following notation is used in the section. Let $x_j \geq 0$ denote the j th fixed experimental dose for $j = 1, \dots, J$, where J is the total number of experimental doses. Without loss of generality, let $x_1 = 0$ be the control dose and $x_1 < x_2 < \dots < x_J$. Let Y_{ij} denote the binary random variable, where $Y_{ij} = 1$ if the i th experimental unit treated at dose x_j shows a toxic outcome and $Y_{ij} = 0$ otherwise. Let π_j denote the unknown probability of observing $Y_{ij} = 1$ (ie, the probability of observing a toxic outcome at dose x_j). Let n_j denote the number of experimental units observed at dose x_j , and let $N = \sum_j n_j$ denote the total sample size for the experiment.

Logistic Regression Model

To model a potential “J-shaped” dose–response relationship, a logistic regression model with the quadratic term

$$\log\left(\frac{\pi_j}{1 - \pi_j}\right) = \beta_0 + \beta_1 x_j + \beta_2 x_j^2$$

is briefly discussed by May and Bigelow.³ They considered the log dose, but it is not an important distinction in our discussion. Throughout the article, the logistic regression model is referred to as the L3 model, where L3 stands for the logistic regression model with 3 parameters β_0 , β_1 , and β_2 . The quadratic term allows a hormetic dose–response curve at low doses, and similar parameterizations are discussed by Bogen⁶ and Kim et al⁷ using different link functions. In the quadratic form, hypothesis testing for hormesis is simply formulated as $H_0: \beta_1 \geq 0$ versus $H_1: \beta_1 < 0$. In a large sample, we can make inference for β_1 based on the maximum likelihood estimator for β_1 , but we usually do not observe such a large sample size particularly inside the hormetic range in practice.³ In this article, we base our inference on bootstrapping to approximate the sampling distribution of the maximum likelihood estimator for β_1 .¹⁵ Our focus is on the consequence of wrong implementation of this model.

The L3 model is an efficient statistical strategy when it is correctly specified. On the other hand, when the model is misspecified, it can lead us to a misleading result even in a large sample. Under model misspecification, observations made at




Figure 2. Hormetic dose–response relationships generated by the logistic regression models. The left figure is the L3 model with $\beta_0 = -1.5$, $\beta_1 = -5$, and $\beta_2 = 10$, the middle figure is the L4 model with $\beta_0 = -1.5$, $\beta_1 = -5$, $\beta_2 = 10$, and $\beta_3 = 0.5$, and the right figure is the L4 model with $\beta_0 = -1.5$, $\beta_1 = -5$, $\beta_2 = 10$, and $\beta_3 = 2$.

high experimental doses have too much contribution in the estimation of β_1 (known as high-leverage points), and it can significantly decrease statistical power. Motivated by a power transformation described by Tukey transformation,¹⁶ the L3 model can be modified as

$$\log\left(\frac{\pi_j}{1 - \pi_j}\right) = \beta_0 + \beta_1(x_j)^{\beta_3} + \beta_2(x_j^2)^{\beta_3}$$

where $\beta_3 > 0$. This parameterization is referred to as the L4 model, where L4 stands for the logistic regression with 4 parameters β_0 , β_1 , β_2 , and β_3 . A similar parameterization was discussed by Kim et al.¹⁷ Compared to the L3 model, the L4 model is more flexible while it maintains the same form of hypothesis testing $H_0: \beta_1 \geq 0$ versus $H_1: \beta_1 < 0$. As shown in Figure 2, the L3 model is limited to a symmetric hormetic zone only (figure on the left), and the L4 model is able to generate an asymmetric hormetic zone by adding the power parameter β_3 (figures in the middle and on the right). Note that the L3 model is a special case of the L4 model when $\beta_3 = 1$.

Model Averaging in Parametric Models (L3 and L4)

The advantage of the L3 model is efficiency (high statistical power) when the true hormetic zone is symmetric and the true dose–response relationship follows the quadratic form. The disadvantage is a loss of statistical power when the model is misspecified. It is also sensitive to high-leverage points. The impact of model misspecification and high-leverage points can be increased particularly when the experiment is poorly designed. On the other hand, the advantage of the L4 model is flexibility, and it can maintain relatively high statistical power when the true hormetic zone is asymmetric. The disadvantage of L4 is a loss of statistical power due to overparameterization when the true hormetic dose–response relationship can be adequately modeled by the L3 model. To compromise the characteristics of L3 and L4, we may consider the model averaging method based on the AIC.⁹ The method of AIC

model averaging is often used to account for model uncertainty and to reduce the impact of model misspecification when a single model is used for inference.^{10,18,19}

Let w_{L3} and w_{L4} denote the AIC weight calculated from the observed data, where $w_{L3} + w_{L4} = 1$ (see Appendix). When a fitted model has a higher value of the likelihood function than the other fitted model, it receives a higher weight. In addition, it penalizes an additional model parameter to balance between goodness of fit and overparameterization. When we have 2 bootstrap distributions from L3 and L4, we can consider a mixture distribution according to the AIC weights. Since both L3 and L4 determine hormesis by the sign of β_1 , we can perform the hypothesis testing $H_0: \beta_1 \geq 0$ versus $H_1: \beta_1 < 0$ based on the mixture distribution of estimated β_1 . At significance level $\alpha = .05$, we reject H_0 in favor of H_1 when the $(1 - \alpha)$ th quantile of the distribution is below 0. Throughout the discussion, this model averaging method is referred to as MA_P (model averaging with the parameter models). When H_0 is true, the type I error rate under MA_A is fairly close to the minimum of the type I error rate under L3 and the type I error rate under L4 (see Appendix and Simulation Result).

Averaging β_1 in L3 and β_1 in L4 is a meaningless procedure when our goal is parameter estimation. However, our goal is hypothesis testing not parameter estimation. Though β_1 in L3 and β_1 in L4 have different meanings, both $\beta_1 < 0$ in L3 and $\beta_1 < 0$ in L4 have the same meaning (presence of hormesis) in the context of our hypothesis testing. Under each model using bootstrapping, we may seek evidence for $\beta_1 < 0$ through the bootstrap distribution of estimated β_1 . Therefore, when a mixture bootstrap distribution of estimated β_1 is mostly negative (regardless of magnitude), it may be regarded as evidence for hormesis.

Application of Model Averaging to Semiparametric Models

Recall that we let π_j denote the probability of a toxic outcome at dose x_j . In general, we need evidence for $\pi_1 > \pi_2$ to reject H_0

in favor of H_1 . In this section, we introduce a proposed model averaging method which does not require a link function between the probability of a toxic outcome and the dose.

Let M_1 denote the saturated model with J free parameters, $\pi_1, \pi_2, \dots, \pi_J$, so each π_j is estimated by the observed proportion at dose x_j . Let M_2 denote a model with $J - 1$ free parameters by the condition $\pi_2 = \pi_3$, so π_2 is estimated by the observed proportion at the 2 doses x_2 and x_3 . Let M_3 denote a model with $J - 2$ free parameters by the condition $\pi_2 = \pi_3 = \pi_4$, so π_2 is estimated by the observed proportion at the 3 doses x_2, x_3 , and x_4 . Using general notation, let M_k denote the model with $J - k + 1$ free parameters such that $\pi_2 = \dots = \pi_{k+1}$. We consider up to M_{J-2} and obtain the AIC-weights w_1, \dots, w_{J-2} by maximizing the log-likelihood function (see Appendix for detail). When we have more experimental units inside the hormetic range, the model averaging will become more robust regardless of the values of x_1, \dots, x_J because the model structure depends on the order x_1, \dots, x_J and estimated π_1, \dots, π_J . It does not assume a particular shape of dose-response curve.

For each M_k , we can obtain the bootstrap distribution of estimated $\pi_1 - \pi_2$, then we test for hypothesis testing $H_0: \pi_1 - \pi_2 \leq 0$ versus $H_1: \pi_1 - \pi_2 > 0$ based on the mixture of the $J - 2$ bootstrap distributions weighted by the AIC weights. At significance level α , we reject H_0 in favor of H_1 when the α th quantile of the mixture distribution exceeds 0. Throughout the discussion, this model averaging method is referred to as MA_{SP} (model averaging with semiparametric models).

Results

In this section, we compare the operating characteristics of the 4 aforementioned models: L3, L4, MA_P , and MA_{SP} . We consider 16 simulation scenarios with 5 scenarios under H_0 and 11 scenarios under H_1 (see Simulation Design). We summarize the simulation results by the probability of rejecting H_0 under each scenario and for each model (see Simulation Result). Then, we apply the 4 models to the data discussed in Calabrese and Baldwin¹⁴ which provided some degree of evidence for hormesis at low doses (see Application).

Simulation Design

To control noise in the simulation, for all 16 scenarios, we assumed $J = 6$ experimental doses geometrically spaced as $x_1 = 0$, $x_2 = 0.0625$, $x_3 = 0.125$, $x_4 = 0.25$, $x_5 = 0.5$, and $x_6 = 1$, and we assumed $n_j = 50$ for each dose group so that $N = 300$ is the total sample size. For the case of H_0 , we generated data under the logistic models L_3 or L_4 (scenarios 1-5). For the case of H_1 , we generated data under L_3 (scenarios 6 and 7), L_4 (scenarios 8-13) and neither (scenarios 14-16).

The scenarios under the parametric structures are shown in Figure 3 (scenarios 1-13). For these parametric scenarios, the parameter values are presented in Table 1. For scenarios 14 to 16, we broke the parametric structures, so both L_3 and L_4 are misspecified models in the 3 scenarios. We made pointwise assumptions $\pi_1 = 0.2$, $\pi_2 = 0.09$, $\pi_3 = 0.1$, $\pi_4 = 0.2$, $\pi_5 =$

0.4, and $\pi_6 = 0.6$ in scenario 14; 0.2, 0.09, 0.07, 0.2, 0.4, and 0.6 in scenario 15, respectively; and 0.2, 0.07, 0.08, 0.2, 0.4, and 0.6 in scenario 16, respectively. Each scenario was simulated 1000 times, and 2000 bootstrap samples were used per simulated sample. We fixed the significance level at $\alpha = .05$, and the probability of rejecting H_0 was recorded for each method under each scenario.

Simulation Result

Table 2 provides the simulation results. When H_0 was true in scenarios 1 to 5, the L_3 model violated $\alpha = .05$ in some scenarios at mild degree, and the L_4 model violated $\alpha = .05$ at serious degree in scenario 2. The estimated type I error probability was .082 which is difficult to believe that it just happened by chance for 1000 replications of the scenario. In each scenario, the model averaging method MA_P rejected H_0 with a probability between the resulting probabilities in L_3 and L_4 with an anticipated result. The model averaging method MA_{SP} obeyed $\alpha = .05$ in the 5 null scenarios.

In scenarios 6 and 7, when H_1 was true under the L_3 model, the L_4 model led to slightly lower statistical powers than the L_3 model due to overparameterization. The MA_P model yielded statistical power between the results in M_3 and M_4 as anticipated. On the other hand, the MA_{SP} yielded substantially lower statistical powers in the 2 scenarios. When the true dose-response curve is generated under the simple L_3 model, the L_3 model outperformed which is not surprising.

In scenarios 8 to 13, when H_1 was true under the L_4 model, the L_3 model could not tolerate model misspecification by showing substantially lower statistical powers due to the inflexibility. The L_4 model mostly showed outperformance because the scenarios belong to its own parameterization. In these 6 scenarios, the MA_{SP} model was consistently more powerful than the MA_P model despite the contribution of the true L_4 model to MA_P . In scenarios 9 to 11, the MA_{SP} model showed comparable results to the results from the true L_4 model.

We now turn our focus on scenarios 14, 15, and 16. Recall that these 3 scenarios did not belong to any of L_3 , L_4 , MA_P , and MA_{SP} . The M_3 model could not reject H_0 even once, the L_4 model showed statistical powers of .180, .200, and .268, respectively, and the MA_P model showed statistical powers of .107, .144, and .200, respectively. On the other hand, the MA_{SP} showed statistical powers of .438, .580, and .666, respectively.

The take-home message is clear. The parametric L_3 and L_4 models sometimes showed outperformance within their own parameterizations (statistical power of .984 and .998 from L_3 in scenarios 6 and 7, respectively; statistical power of .570, .474, .706, .525, and .768 from L_4 in scenarios 8, 9, 10, 12 and 13, respectively; see Table 2), but they performed poorly when the truth was not under the model (statistical power of 0 from L_3 in scenarios 14, 15, and 16; statistical power of .180, .200, and .268 from L_4 in scenarios 14, 15, and 16 which are less than one half when compared to .438, .580, and .666 from MA_{SP} in the respective scenarios; see Table 2). This is a




Figure 3. Simulation scenarios generated by the logistic models (scenarios 1-13). The parameter values are provided in Table 1.

Table 1. Parameter Values for Scenarios 1 to 13 Under the Logistic Model.

Scenario	1	2	3	4	5	6	7	8	9	10	11	12	13
β_0	-1.3	-1.3	-1.3	-1.3	-2.3	-1.39	-1.39	-1.39	-1.39	-1.39	-1.39	-1.39	-1.39
β_1	0	0	0	0	0	-7.33	-10.02	-5.18	-4.62	-7.09	-6.31	-7.33	-10.02
β_2	0	1	3	1	3	14.66	20.04	7.33	5.82	10.02	7.95	14.66	20.04
β_3	0	1	1	.5	.5	1	1	.5	.33	.5	.33	.5	.5

general phenomenon in statistics. On the other hand, the MA_{SP} model was relatively less sensitive, and the model averaging among the semiparametric model (MA_{SP}) showed greater statistical power than the model averaging among the parametric models (MA_P) in the scenarios except when L3 was the true model (see scenarios 8-16 in Table 2).

Application

In this section, we apply the 4 models (L3, L4, MA_P , and MA_{SP}) to some of binary data discussed in Calabrese and Baldwin¹⁴ and compare P values from the 4 models.

Calabrese and Baldwin¹⁴ discussed the effects of saccharin on hyperplasia of the urinary bladder. The 6 experimental doses were 0, .01, .1, 1, 5, and 7.5 (% in diets). The respective observed proportions of tumor incidence were 10/73 (14%), 6/71 (8%), 4/81 (5%), 4/76 (5%), 6/64 (9%), and 19/62 (31%) for male rats (see the top left panel in Figure 4). When we implemented the L3, L4, MA_P , and MA_{SP} models, the respective P values were .042, .027, .034, and .059, respectively. This is one of the cases when the parametric models adequately described the dose-response relationships, and the MA_{SP} model could not achieve the significance level $\alpha = .05$. At the same experimental doses, the respective observed

Table 2. Simulation Results, the Probability of Rejecting H_0 Based on 1000 Simulated Data per Scenario.^a

Scenario	True Model	L3	L4	MA _P	MA _{SP}
1	L3/L4	.055	.044	.042	.044
2	L3/L4	.056	.082	.061	.037
3	L3/L4	.019	.029	.018	.020
4	L3/L4	.066	.038	.043	.025
5	L3/L4	.000	.003	.000	.019
6	L3	.984	.764	.894	.279
7	L3	.998	.845	.948	.400
8	L4	.277	.570	.467	.474
9	L4	.135	.474	.327	.470
10	L4	.387	.706	.641	.673
11	L4	.145	.635	.517	.689
12	L4	.318	.525	.446	.475
13	L4	.453	.768	.660	.670
14	—	.000	.180	.107	.438
15	—	.000	.200	.144	.580
16	—	.000	.268	.200	.666

^aL3 represents logistic regression model with the 3 parameters β_0 , β_1 , and β_2 ; L4, logistic regression model with the 4 parameters β_0 , β_1 , β_2 , and β_3 ; MA_P, model averaging with the parametric models L3 and L4; MA_{SP}, model averaging with the semiparametric models.

proportions of incidence were 3/85 (4%), 0/81 (0%), 0/81 (0%), 3/90 (3%), 5/88 (6%), and 10/76 (13%) for female rats (see the top right panel in Figure 4). When we implemented the L3, L4, MA_P, and MA_{SP} models, the respective P values were .811, .070, .207, and .014, respectively. As shown in the figure (the top right panel), the data points in the observed range are not symmetric, so the L3 model was not able to model the observed nonmonotonic dose–response relationship adequately.

Calabrese and Baldwin¹⁴ also discussed the effect of 3-Methylcholanthrene on pulmonary tumors in female rats. The 9 experimental doses were 0, .005, .015, .046, .137, .4, 1.2, 3.7, and 11.1 (μg). The observed proportions of tumor incidence were 15/34 (44%), 1/18 (6%), 5/19 (26%), 7/18 (39%), 6/20 (30%), 12/24 (50%), 8/11 (73%), 10/10 (100%), and 11/11 (100%), respectively (see the bottom left panel in Figure 4). Compared to the previous data set (effect of saccharin on urinary bladder), it has a smaller total sample size but a larger number of experimental doses. The L3, L4, MA_P, and MA_{SP} models yielded P values of .869, .070, .224, and .003, respectively. As shown in Figure 4 (the bottom left panel), the L3 model was not flexible enough to describe the observed data, and the L4 model was quite flexible to follow the observed nonmonotonic trend though it did not achieve statistical significance. Under the MA_{SP} model, the data served as significance evidence for hormesis with a P value $.003 < \alpha = .05$.

As a final example, the same paper¹⁴ discussed the effect of cadmium chloride on testicular tumors. From the 7 experimental doses 0, 1, 2.5, 5, 10, 20, and 40 ($\mu\text{mol/kg}$), the observed proportions of incidence were 8/45 (17.8%), 1/30 (3.3%), 3/29 (10.3%), 3/30 (10.0%), 4/30 (13.3%), 21/29 (72.4%), and 24/29 (82.8%), respectively (see the bottom right panel in Figure 4).

Despite the strong hormetic trend, P values from L3, L4, MA_P, and MA_{SP} were .99, .64, .65, and .06, respectively, and they seem to be influenced by the 2 data points at the high doses 20 and 40 $\mu\text{mol/kg}$. The P values from the parametric methods (L3, L4, and MA_P) do not seem credible, and the P value from averaging the semiparametric models seems more credible based on the observed trend before modeling. In the figure (the bottom right panel), the L3 model was not able to model the asymmetric hormetic trend, and the flexibility of the L4 model was used to chase the 2 data points at the high experimental doses rather than the data points at low doses. An interesting issue with the L4 model is discussed in the following section.

Discussion

The focus of this article is not to argue the existence of hormesis for a particular carcinogen. Our focus is a valid hypothesis testing for a hormetic effect at low doses. We presented the different characteristics of averaging parametric models and averaging semiparametric models. In conclusion, when the true hormetic relationship is under the simple L3 model, the parametric approach MA_P (and individual L3 and L4) outperformed the semiparametric approach MA_{SP}, which is not surprising. On the other hand, when we compare the 2 averaging methods, MA_{SP} outperformed MA_P when the true hormetic relationship is nonparametric and even when the truth is generated under the parametric L4 model. It is also shown that the parametric approaches cannot tolerate model misspecification for the hypothesis testing. To this end, when the truth does not follow a parametric form, MA_{SP} can be useful for more robust and higher statistical power.

In large sample studies with many experimental doses in a hormetic range, a nonparametric method can be a more reasonable approach because it can disconnect information between doses inside a hormetic range and higher doses. May and Bigelow³ discussed the practical challenges due to insufficient sample sizes and a lack of experimental doses (missing a potential hormetic range). In small sample studies, borrowing mathematical structure (ie, parametric models) to gain efficiency seems inevitable. As discussed in “Results,” however, it sometimes gives us a misleading result not simply due to a lack of evidence but due to model misspecification and high-leverage data points (recall the low statistical power from L3, L4, and MA_P in scenarios 14–16 in Table 2). Motivated by this fact, we considered averaging semiparametric models (MA_{SP}) with AIC weights to test for a hormetic effect at low doses. When we implemented to real data, calculated P values from MA_{SP} made more sense than P values from L3, L4, and MA_P particularly in the last applied example in “Application” (cadmium chloride on testicular tumors).

In the simulation study, we showed pros and cons of the parametric methods (L3, L4, and MA_P) and of the semiparametric method (MA_{SP}). Under the correctly specified parametric form, the statistical power from L3 was highest among the 4 methods as shown in scenarios 6 and 7 in Table




Figure 4. Fitted dose–response curves under the L3 and L4 models using the maximum likelihood estimates.

2, and MA_P outperformed MA_{SP} in the 2 scenarios generated by L3. Under the wrong parametric form, we lost statistical power substantially as shown in scenarios 14 to 16 (zero statistical power from L3 in Table 2). We observed that MA_{SP} outperformed MS_P in the 3 scenarios generated outside of L3 or L4. Even when the true scenario was generated by L4, MA_{SP} could yield higher statistical power than MA_P as shown in scenarios 8 to 13 (see Table 2). In practice, we cannot guarantee that observed outcomes (which are based on the unknown true dose–response relationship) will follow a parametric model as seen in the cadmium chloride data, and it is not under our control. Instead, the proposed model averaging method with semiparametric models does not require the parametric form, and we learned that it is relatively less sensitive to the shape of observed dose–response trend.

For the L4 model, we refitted the cadmium chloride data with the restriction $0 < \beta_3 < 1$. The restricted parameterization yielded a P value lower than $\alpha = .05$ by adequately modeling the asymmetric hormetic zone. However, when we ran a simulation study under the null scenarios, it violated the significance

level $\alpha = .05$ seriously. In other words, the restricted parameterization tended to favor H_1 too often when H_0 is true. Additionally, we implemented the nonparametric regression method discussed in Hall and Heckman²⁰ in the simulation study. The advantage of a nonparametric method is insensitivity to data points at high doses, but it yielded lower statistical powers than MA_{SP} in all of the alternative scenarios (generally below .2). We also studied other methods among others. We modified the test statistic in Baraud et al.,²¹ which is more appropriate for the binomial data (ie, difference in the 2 probabilities, comparing the control group and the lowest nonzero dose group). It tended to be too conservative, and it did not seem appropriate for a sparse experimental doses. Similarly, we tested an umbrella shape at low doses (decreasing then increasing) using the additive constrained regression.²² Due to the small number of dose groups, the model fitted the data exactly, and it inflated the type I error rate in null scenarios. A nonparametric method is often useful for a large sample study, but 50 experimental units per dose group with 6 experimental units do not seem sufficiently large particularly for binary outcomes.

To further study L3, L4, MA_P, and MA_{SP} for increased sample sizes (fixing the experimental doses), we manipulated the cadmium chloride data by doubling the sample size while maintaining the observed proportions, that is 16/90 (17.8%), 2/60 (3.3%), 6/58 (10.3%), 6/60 (10.0%), 8/60 (13.3%), 42/58 (72.4%), and 48/58 (82.8%). Recall the P values were .99, .64, .65, and .06 for L3, L4, MA_P, and MA_{SP}, respectively, before the manipulation (see Application). After the manipulation, the P values changed to .999, .727, .727, and .006 for L3, L4, MA_P, and MA_{SP}, respectively. When we multiplied the sample size by 10, that is 80/450 (17.8%), 10/300 (3.3%), 30/290 (10.3%), 30/300 (10.0%), 40/300 (13.3%), 210/290 (72.4%), and 240/290 (82.8%), the P values were close to 1, .943, .943, and close to 0 for L3, L4, MA_P, and MA_{SP}, respectively. Then, we tested an additional simulation scenario under the assumptions (1) $\pi_1 = .178$, $\pi_2 = .033$, $\pi_3 = .103$, $\pi_4 = .100$, $\pi_5 = .133$, $\pi_6 = .724$, and $\pi_7 = .828$ and (2) $n_1 = 450$, $n_2 = 300$, $n_3 = 290$, $n_4 = 300$, $n_5 = 300$, $n_6 = 290$, and $n_7 = 290$. The resulting statistical powers were near 0, .005, .005, and near 1 for L3, L4, MA_P, and MA_{SP}, respectively. The results illustrate the impact of model misspecification even with large data under the parametric methods when we test for hormesis.

The Generic Hockey Stick model proposed by Bogen⁶ is a parametric model with the enhanced polynomial flexibility and the link function used in the linearized multistage model.²³ In sparse data, it may have the advantage of utilizing 3 parameters to allow greater flexibility than the L3 models considered in this study. However, the Fisher expected information tells us that the parameter estimation still heavily depends on high data points when we use a polynomial predictor. In practice, high-response data are removed when (1) they are irrelevant to low-dose inference and (2) they severely deviate from an assumed parametric model. We concern about too few data points after removing the data points, and it may increase the type I error rate under the null scenario. It is our future study.

Based on the simulation study, we have thought that averaging L4 and MA_{SP} can balance the sensitivity (when the observed data points can be approximated by the assumed parametric structure) and the robustness (when they do not follow the assumed parametric structure). It is our current research direction.

Appendix

Model Averaging of L3 and L4

Let $y_{ij} = 1$ if we observe the i th experimental unit treated by dose x_j showed a toxic outcome (and $y_{ij} = 0$ otherwise) for $i = 1, \dots, n_j$ and $j = 1, \dots, J$ (see Model Averaging in Parametric Models [L3 and L4] subsection). Let π_j denote the probability of observing a toxic event at dose x_j which is unknown for $j = 1, \dots, J$. Given the data, the log-likelihood function is

$$l = \sum_{j=1}^J \sum_{i=1}^{n_j} \left(y_{ij} \log(\pi_j) + (1 - y_{ij}) \log(1 - \pi_j) \right)$$

The L3 model assumes

$$\pi_j = \frac{e^{\beta_0 + \beta_1 x_j + \beta_2 x_j^2}}{1 + e^{\beta_0 + \beta_1 x_j + \beta_2 x_j^2}}$$

so l is a function of β_0 , β_1 , and β_2 , denoted by $l_{L3}(\beta_0, \beta_1, \beta_2)$. The L4 model assumes

$$\pi_j = \frac{e^{\beta_0 + \beta_1 x_j^{\beta_3} + \beta_2 x_j^{2\beta_3}}}{1 + e^{\beta_0 + \beta_1 x_j^{\beta_3} + \beta_2 x_j^{2\beta_3}}}$$

so l is a function of β_0 , β_1 , β_2 , and β_3 , denoted by $l_{L4}(\beta_0, \beta_1, \beta_2, \beta_3)$. Let \hat{l}_{L3} denote the maximized $l_{L3}(\beta_0, \beta_1, \beta_2)$ with respect to $(\beta_0, \beta_1, \beta_2)$, and let \hat{l}_{L4} denote the maximized $l_{L4}(\beta_0, \beta_1, \beta_2, \beta_3)$ with respect to $(\beta_0, \beta_1, \beta_2, \beta_3)$. The AIC of the L3 model is defined as $AIC_{L3} = -2\hat{l}_{L3} + 2p = -2\hat{l}_{L3} + 6$ because the model has $p = 3$ parameters. The AIC of the L4 model is defined as $AIC_{L4} = -2\hat{l}_{L4} + 2p = -2\hat{l}_{L3} + 8$ because it has $p = 4$ parameters. Then the AIC weight of the L3 model and of the L4 model is

$$w_{L3} = \frac{e^{-0.5AIC_{L3}}}{e^{-0.5AIC_{L3}} + e^{-0.5AIC_{L4}}}, \quad w_{L4} = \frac{e^{-0.5AIC_{L4}}}{e^{-0.5AIC_{L3}} + e^{-0.5AIC_{L4}}},$$

respectively.

Type I Error Rate Under MA_P

Assume the null hypothesis H_0 is true (see Model Averaging in Parametric Models [L3 and L4] subsection). Let B denote the number of bootstrap samples. Let w be a number between 0 and 1 (ie, AIC weight). Let p_3 denote the proportion of bootstrap estimates such that $\beta_1 > 0$ under the L3 model. Consider a significance level $\alpha = .05$. In this case, under the L3 model, we reject H_0 in favor of H_1 when $B \times p_3 < .05 \times B$. Similarly, let p_4 denote the proportion of bootstrap estimates such that $\beta_1 > 0$ under the L4 model. Under the L4 model, we reject H_0 in favor of H_1 when $B \times p_4 < .05 \times B$. Now, consider a mixture bootstrap distribution of estimated β_1 (ie, averaging the 2 bootstrap distributions from L3 and L4). If L3 is weighted by w and L4 is weighted by $1 - w$, we reject H_0 in favor of H_1 when $B [w \times p_3 + (1 - w) \times p_4] < .05 \times B$ under the model averaging MA_P. Now let R_3 , R_4 , and R_{MA} denote the event that H_0 is rejected under L3, L4, and MA_P, respectively. We consider the 4 cases. If $R_3 \cap R_4$ occurs, it implies R_{MA} (case 1). If $R_3 \cap R_4^C$ occurs (ie, H_0 is rejected under L3 but not under L4), it is inconclusive (case 2). If $R_3^C \cap R_4$ occurs, it is inconclusive (case 3). If $R_3^C \cap R_4^C$ occurs, it implies R_{MA}^C . To this end,

$$\begin{aligned} P(R_{MA}) &\leq P(R_3 \cap R_4) + P(R_3 \cap R_4^C) + P(R_3^C \cap R_4) \\ &= P(R_3) + P(R_3^C \cap R_4) \end{aligned}$$

and

$$\begin{aligned} P(R_{MA}) &\leq P(R_3 \cap R_4) + P(R_3 \cap R_4^C) + P(R_3^C \cap R_4) \\ &= P(R_4) + P(R_3 \cap R_4^C) \end{aligned}$$

In other words, the type I error rate under MA_P has the upper bound

$$P(R_{MA}) \leq \min\{P(R_3) + P(R_3^C \cap R_4), P(R_4) + P(R_3 \cap R_4^C)\}$$

If we observe an unusual original sample against H_0 , both the probability of R_3 and the probability of R_4 increase, so $P(R_3^C \cap R_4)$ and $P(R_3 \cap R_4^C)$ are fairly small. To this end, the type I error rate under MA_P cannot be too far away from a range between the type I error rate under L_3 and under L_4 . In the simulation study (“Simulation Result” and Table 2), we observe that $P(R_{MA})$ is close to the minimum of $P(R_3)$ and $P(R_4)$ under the null scenarios (scenarios 1-5).

Model Averaging of M_1, \dots, M_{J-2}

Assuming model M_k , for $k = 1, \dots, J - 2$, the log-likelihood function is given by (see Application of Model Averaging to Semiparametric Models subsection)

$$l_k(\pi_1, \dots, \pi_J) = \sum_{j=1}^J \sum_{i=1}^{n_j} \left(y_{ij} \log(\pi_j) + (1 - y_{ij}) \log(1 - \pi_j) \right)$$

with the restriction $\pi_2 = \dots = \pi_{k+1}$.

- For model M_1 , it is the saturated model, so the maximum \hat{l}_1 can be achieved by letting $\pi_j = \sum_i y_{ij}/n_j$, the observed proportion of toxic outcomes at dose x_j .
- For model M_2 with the restriction $\pi_2 = \pi_3$, the maximum \hat{l}_2 can be achieved by letting $\pi_j = \sum_i y_{ij}/n_j$ for j not being equal to 2 or 3 and $\pi_2 = \pi_3 = (\sum_i y_{i2} + \sum_i y_{i3})/(n_2 + n_3)$ which is the pooled estimation.
- For model M_3 , with the restriction $\pi_2 = \pi_3 = \pi_4$, the maximum \hat{l}_3 can be achieved by letting $\pi_j = \sum_i y_{ij}/n_j$ for j not being equal to 2, 3, or 4 and $\pi_2 = \pi_3 = \pi_4 = (\sum_i y_{i2} + \sum_i y_{i3} + \sum_i y_{i4})/(n_2 + n_3 + n_4)$.
- This pattern continued up to M_{J-2} , where J is the number of fixed experimental doses.

The AIC of model M_k is $AIC_k = -2\hat{l}_k + 2p_k$, where $p_k = J - k + 1$ is the number of free parameters in the model. Then the AIC weight of M_k is given by

$$w_k = \frac{e^{-0.5AIC_k}}{e^{-0.5AIC_1} + \dots + e^{-0.5AIC_{J-2}}}$$

Acknowledgments

The authors appreciate the comments and suggestions from reviewers.

Declaration of Conflicting Interests

The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Funding

The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This research was supported by Undergraduate Research Opportunities Center (UROC) at California State University, Monterey Bay (CSUMB). Nathan Sanders was supported by the HSI Grant (US Department of Education Hispanic-Serving Institutions Program (STEM) Program (84.031C)—Grant #P031V11021).

References

1. Mattson MP. Hormesis defined. *Ageing Res Rev.* 2008;7(1):1-7.
2. Calabrese EJ. Hormesis: a revolution in toxicology, risk assessment and medicine. *EMBO Rep.* 2004;5(suppl 1):S37-S40.
3. May S, Bigelow C. Modeling nonlinear dose-response relationships in epidemiologic studies: statistical approaches and practical challenges. *Dose Response.* 2005;3(4):474-490.
4. United States Environmental Protection Agency. Benchmark Dose Software (BMDS) Version BMDS: 2.6.0.1. <https://www.epa.gov/bmds/download-benchmark-dose-software-bmds>. 2016. Updated 2016. Accessed March 2017.
5. Hunt DL, Bowman D. A parametric model for detecting hormetic effects in developmental toxicity studies. *Risk Anal.* 2004;24(1):65-72.
6. Bogen KT. Generic hockey-stick model for estimating benchmark dose and potency: performance relative to BMDS and application to anthraquinone. *Dose Response.* 2011;9(2):182-208.
7. Kim SB, Bartell SM, Gillen DL. Estimation of a benchmark dose in the presence or absence of hormesis using posterior average. *Risk Anal.* 2015;35(3):396-408.
8. Everitt BS, Skrondal A. *The Cambridge Dictionary of Statistics*, 4th ed. New York, NY: Cambridge University Press; 2010.
9. Akaike H. A new look at the statistical model identification. *IEEE Trans Autom Control.* 1974;19(6):716-723.
10. Bailer AJ, Noble RB, Wheeler MW. Model uncertainty and risk estimation for experimental studies of quantal responses. *Risk Anal.* 2005;25(2):291-299.
11. Moon H, Kim H, Chen JJ, Kodell RL. Model averaging using the Kullback information criterion in estimating effective doses for microbial infection and illness. *Risk Anal.* 2005;25(5):1147-1159.
12. Wheeler MW, Bailer AJ. Properties of model-averaged BMDLs: a study of model averaging in dichotomous response risk estimation. *Risk Anal.* 2007;27(3):659-670.
13. Shao K, Small MJ. Potential uncertainty reduction in model-averaged benchmark dose estimates informed by an additional dose study. *Risk Anal.* 2011;31(10):1156-1175.
14. Calabrese EJ, Baldwin LA. Can the concept of hormesis be generalized to carcinogenesis? *Regul Toxicol Pharmacol.* 1998;28(3):230-241.
15. Efron B. Bootstrap methods: another look at the jackknife. *Ann Stat.* 1979;7(1):1-26.
16. Tukey JW. *Exploratory Data Analysis*. Reading, PA: Addison-Wesley; 1977.
17. Kim SB, Bartell SM, Gillen DL. Inference for the existence of hormetic dose-response relationships in toxicology studies. *Bio-statistics.* 2016;17(3):523-536.

18. Kang SH, Kodell RL, Chen JJ. Incorporating model uncertainties along with data uncertainties in microbial risk assessment. *Regul Toxicol Pharmacol.* 2000;32(1):68-72.
19. Piegorsch WW, An L, Wickens AA, West RW, Pena EA, Wu W. Information-theoretic model-averaged benchmark dose analysis in environmental risk assessment. *Environmetrics.* 2013;24(3):143-157.
20. Hall P, Heckman NE. Testing for monotonicity of a regression mean by calibrating for linear functions. *Ann Stat.* 2000;28(1):20-39.
21. Baraud Y, Huet S, Laurent B. Testing convex hypotheses on the mean of a Gaussian vector: application to testing qualitative hypotheses on a regression function. *Ann Stat.* 2005;33(1):214-257.
22. Meyer MC. Semi-parametric additive constrained regression. *J Nonparametric Stat.* 2013;25(3):715-730.
23. Anderson EL, Albert RE, McGaughy R, et al. Quantitative approaches in use to assess cancer risk. *Risk Anal.* 1983;3(4):277-295.